CN105412920A - 含有突变型ｈ因子结合蛋白的疫苗组合物 - Google Patents

含有突变型ｈ因子结合蛋白的疫苗组合物 Download PDF

Info

Publication number
CN105412920A
CN105412920A CN201510119007.XA CN201510119007A CN105412920A CN 105412920 A CN105412920 A CN 105412920A CN 201510119007 A CN201510119007 A CN 201510119007A CN 105412920 A CN105412920 A CN 105412920A
Authority
CN
China
Prior art keywords
factor
compositions
bindin
factor bindin
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510119007.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·埃克斯利
C·唐
S·M·利亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Publication of CN105412920A publication Critical patent/CN105412920A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201510119007.XA 2008-10-25 2009-10-26 含有突变型ｈ因子结合蛋白的疫苗组合物 Pending CN105412920A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0819633.9 2008-10-25
GBGB0819633.9A GB0819633D0 (en) 2008-10-25 2008-10-25 Composition
CN2009801480003A CN102245202A (zh) 2008-10-25 2009-10-26 含有突变型h因子结合蛋白的疫苗组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801480003A Division CN102245202A (zh) 2008-10-25 2009-10-26 含有突变型h因子结合蛋白的疫苗组合物

Publications (1)

Publication Number Publication Date
CN105412920A true CN105412920A (zh) 2016-03-23

Family

ID=40133849

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801480003A Pending CN102245202A (zh) 2008-10-25 2009-10-26 含有突变型h因子结合蛋白的疫苗组合物
CN201510119007.XA Pending CN105412920A (zh) 2008-10-25 2009-10-26 含有突变型ｈ因子结合蛋白的疫苗组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2009801480003A Pending CN102245202A (zh) 2008-10-25 2009-10-26 含有突变型h因子结合蛋白的疫苗组合物

Country Status (23)

Country Link
US (1) US20120052092A1 (enExample)
EP (2) EP3501534B1 (enExample)
JP (2) JP5676458B2 (enExample)
KR (3) KR20190011836A (enExample)
CN (2) CN102245202A (enExample)
AU (1) AU2009306114B2 (enExample)
BR (1) BRPI0919926A2 (enExample)
CA (1) CA2741619A1 (enExample)
CO (1) CO6382140A2 (enExample)
DK (1) DK3501534T5 (enExample)
ES (1) ES2970878T3 (enExample)
FI (1) FI3501534T3 (enExample)
GB (1) GB0819633D0 (enExample)
HR (1) HRP20240226T1 (enExample)
HU (1) HUE065348T2 (enExample)
LT (1) LT3501534T (enExample)
MX (1) MX2011004322A (enExample)
NZ (2) NZ601538A (enExample)
PL (1) PL3501534T3 (enExample)
PT (1) PT3501534T (enExample)
RU (1) RU2559528C2 (enExample)
SI (1) SI3501534T1 (enExample)
WO (1) WO2010046715A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
CA2838395C (en) 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
DE60144353D1 (de) 2000-02-28 2011-05-12 Novartis Vaccines & Diagnostic Hybride Expression Neisserscher Proteine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
HUE047780T2 (hu) 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
RU2475496C2 (ru) 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
CA2717870A1 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
AU2010242905B2 (en) 2009-04-30 2014-10-23 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHbp) and methods of use
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
BR112012022669A2 (pt) * 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
EP2861247B1 (en) 2012-06-14 2020-12-09 GlaxoSmithKline Biologicals SA Vaccines for serogroup x meningococcus
EP2877492A1 (en) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
BR112016002150A2 (pt) 2013-08-02 2017-09-12 Children´S Hospital & Res Center At Oakland proteínas de ligação de fator h de ocorrência natural (fhbp) e métodos de uso das mesmas
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
WO2016014719A1 (en) * 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Factor h binding protein variants and methods of use thereof
IL250667B2 (en) * 2014-08-20 2023-10-01 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
MX2021007539A (es) 2018-12-21 2021-09-21 Univ Griffith Composiciones, metodos y usos para provocar una respuesta inmune.
EP3997108A4 (en) * 2019-07-08 2024-03-20 Crapaud Bio, Inc. METHODS OF PRODUCING AND USING LIPOOLIGOSACCHARIDE COMPOSITIONS AND VACCINES
KR20220057530A (ko) 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
AU2022223712A1 (en) 2021-02-19 2023-10-05 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688334A (zh) * 2002-08-30 2005-10-26 启龙有限公司 改进的细菌外膜囊泡
CN1867354A (zh) * 2003-04-16 2006-11-22 惠氏控股有限公司 预防和治疗脑膜炎球菌疾病的新颖免疫原性组合物
WO2007060548A2 (en) * 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2008001224A2 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
JP4993750B2 (ja) * 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のための、ｇｎａ１８７０を基にした小胞ワクチン
BR112012004275A2 (pt) * 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688334A (zh) * 2002-08-30 2005-10-26 启龙有限公司 改进的细菌外膜囊泡
CN1867354A (zh) * 2003-04-16 2006-11-22 惠氏控股有限公司 预防和治疗脑膜炎球菌疾病的新颖免疫原性组合物
WO2007060548A2 (en) * 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2008001224A2 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETER T. BEERNINK,ET AL: "Prevalence of Factor H–Binding Protein Variants and NadA among Meningococcal Group B Isolates from the United States:Implications for the Development of a Multicomponent Group B Vaccine", 《J INFECT DIS.》 *
VEGA MASIGNANI,ET AL: "Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870", 《J. EXP. MED.》 *

Also Published As

Publication number Publication date
FI3501534T3 (fi) 2024-02-09
US20120052092A1 (en) 2012-03-01
CO6382140A2 (es) 2012-02-15
KR20190011836A (ko) 2019-02-07
EP2355845B1 (en) 2018-12-05
GB0819633D0 (en) 2008-12-03
EP3501534B1 (en) 2023-11-29
CN102245202A (zh) 2011-11-16
SI3501534T1 (sl) 2024-03-29
CA2741619A1 (en) 2010-04-29
EP2355845A1 (en) 2011-08-17
JP2012506411A (ja) 2012-03-15
HRP20240226T1 (hr) 2024-05-10
KR20170000390A (ko) 2017-01-02
NZ592444A (en) 2012-11-30
AU2009306114B2 (en) 2015-10-01
DK3501534T5 (da) 2024-09-02
DK3501534T3 (da) 2024-02-05
ES2970878T3 (es) 2024-05-31
BRPI0919926A2 (pt) 2016-02-16
PT3501534T (pt) 2024-02-07
LT3501534T (lt) 2024-03-12
RU2559528C2 (ru) 2015-08-10
AU2009306114A1 (en) 2010-04-29
JP5676458B2 (ja) 2015-02-25
HUE065348T2 (hu) 2024-05-28
NZ601538A (en) 2014-01-31
JP6076326B2 (ja) 2017-02-08
JP2015063558A (ja) 2015-04-09
PL3501534T3 (pl) 2024-04-02
EP3501534A1 (en) 2019-06-26
WO2010046715A1 (en) 2010-04-29
RU2011120706A (ru) 2012-11-27
KR20110092282A (ko) 2011-08-17
MX2011004322A (es) 2011-06-16

Similar Documents

Publication Publication Date Title
CN105412920A (zh) 含有突变型ｈ因子结合蛋白的疫苗组合物
JP6494565B2 (ja) オリゴマー特異アミロイドベータエピトープおよび抗体
CN1306956C (zh) 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
EA012407B1 (ru) Гуманизированный иммуноглобулин, который специфически связывается с бета-амилоидным пептидом, и способы его применения
Granoff et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis
MX2011000134A (es) Vacuna contra el intermediario de plegamiento amiloide.
Aston-Deaville et al. An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis
US11319348B2 (en) Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
CN105407915A (zh) 用于治疗真菌性和细菌性病原体的组合物和方法
US9913889B2 (en) Immunogenic TP0751 fragments
CN101638433B (zh) 保守淋球菌表位的拟肽及应用它们的方法和组合物
US9475864B2 (en) Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
CN114262366B (zh) 幽门螺杆菌HspA的B细胞表位多肽HP11及其应用
Kumru Surface localization determinants of Borrelia burgdorferi lipoproteins
Lambert Identification and Description of Burkholderia pseudomallei Proteins that Bind Host Complement-Regulatory Proteins via in silico and in vitro Analyses
KR0180991B1 (ko) 합성 펩티드를 함유하는 녹농균 백신 및 이것으로부터 생산된 치료제
Principato et al. Investigation of the protective mechanisms mediated by Neisserial Heparin Binding Antigen (NHBA) induced antibodies
AU2017245320A1 (en) Vaccine compositions comprising a mutated factor h binding protein
Menéndez et al. Recent Advances in the Pathogenic Neisseria Research
HK1141034B (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160323

WD01 Invention patent application deemed withdrawn after publication